Can you keep your breast if you have multifocal or multicentric disease?
If you have been diagnosed with multifocal or multicentric breast cancer, you may have been told that mastectomy - removal of the whole breast - is the safest or only surgical choice. For many years that was the standard recommendation, and for some women it still is the right choice. But surgical techniques, imaging, and radiotherapy have all improved significantly, and the evidence has shifted. For selected women, breast-conserving surgery, sometimes combined with robotic or oncoplastic techniques, can now achieve results comparable to mastectomy. First, learn what makes you eligible for different surgical options.
What do multifocal and multicentric mean?
These two terms describe different patterns of multiple tumours in the same breast, and the distinction matters for your surgical options.
- Multifocal means two or more separate tumours develop in the same quadrant - one section - of the breast. They are typically close together and likely share the same cellular origin.
- Multicentric means tumours appear in two or more different quadrants of the same breast. Because they are further apart, removing all of them while preserving the breast is more technically demanding.
Modern breast imaging, particularly MRI, has made it easier to identify additional tumour sites that earlier scans might have missed. Detailed imaging can sometimes show that what seemed like one tumour is actually multifocal or multicentric disease. That's why careful staging matters before surgery.
Having more than one tumour site does not automatically mean your cancer is more aggressive. Your oncologist will look at each tumour's biology - hormone status, HER2 status, and grade - to understand your prognosis and the best treatment options for your case.
Why mastectomy became the standard recommendation
The traditional reasoning was logical. Removing multiple tumours in different parts of the breast while keeping the breast intact is technically demanding. Incomplete excision - leaving cancer cells at the surgical margins - raises the risk of cancer returning in the same breast. Earlier research showed higher recurrence rates when doctors tried breast-conserving surgery for multicentric disease, so the caution made sense.
What's changed is the available technology and surgical techniques. Oncoplastic surgery, better imaging, MRI planning, and stronger radiotherapy have expanded what doctors can safely do. Now the question isn't whether breast conservation works, but which women are candidates for it.
What the current evidence says
A review published in Frontiers in Oncology concluded that breast-conserving surgery can work for multifocal and multicentric breast cancer when doctors can remove all the cancer cleanly, noting that local recurrence rates in contemporary clinical series are broadly comparable to mastectomy.
A retrospective matched-cohort study examining oncoplastic breast-conserving surgery for synchronous - occurring at the same time - multicentric and multifocal tumours found that oncoplastic breast-conserving surgery achieved equivalent results to mastectomy in selected patients, with acceptable cosmetic outcomes.
A systematic review and meta-analysis on local control of breast conservation therapy versus mastectomy in multifocal or multicentric breast cancer, available via PubMed, found that local recurrence rates are broadly similar between the two approaches when radiotherapy is appropriately delivered after breast-conserving surgery in carefully selected patients.
A 2025 narrative literature review of multicentric and multifocal breast tumours published in PMC confirmed that oncoplastic and minimally invasive approaches have extended eligibility for breast preservation in this group, with neoadjuvant systemic therapy helping by reducing tumour size before surgery in some cases.
One phrase keeps appearing across this evidence: "carefully selected." Breast conservation doesn't work for all women with multifocal or multicentric disease. The decision rests on factors specific to your case, set out below.
How robotic surgery fits into this picture
Robotic techniques in breast cancer surgery are most established for nipple-sparing mastectomy. Using a robotic-assisted approach, the surgeon works through a small incision near the armpit rather than a larger chest incision, enabling more precise removal of breast tissue close to the nipple with less visible scarring. If mastectomy is the right choice for you, a robotic approach at a specialist centre may offer better cosmetic results and faster recovery than conventional open mastectomy.
For breast-conserving surgery in multifocal or multicentric disease, the most relevant surgical advance is oncoplastic surgery - a technique that combines tumour removal with plastic-surgical reshaping of the breast. This allows surgeons to remove a larger volume of tissue to achieve clean margins across multiple tumour sites, while rearranging the remaining breast tissue to maintain good cosmetic results. At specialist centres, robotic and minimally invasive tools assist with these more complex removals.
Research published in PMC on extreme oncoplastic breast conservation surgery for complex multifocal and multicentric cases found that this approach can work in selected patients who would otherwise have a mastectomy, with acceptable results reported.
To understand how tumour size more broadly affects eligibility for breast-conserving surgery, our article on tumour size and robotic lumpectomy explains how surgeons weigh the volume to be removed against the feasibility of breast conservation.
Who is - and who is not - likely to be a candidate for breast conservation?
Factors that may support breast-conserving surgery in multifocal or multicentric disease:
- All tumour foci are in the same or adjacent quadrant, or multicentric foci are small enough that clean margins can be achieved in a single combined procedure
- Your breast size relative to the total volume of tissue to be removed allows good cosmetic results
- You are fit and willing to receive radiotherapy after surgery - this is a standard, required part of breast-conserving treatment
- You have responded well to neoadjuvant therapy that has reduced tumour bulk before surgery
- Your cancer biology does not carry features that independently favour mastectomy, such as a confirmed BRCA1 or BRCA2 gene mutation in women who prefer the risk-reduction mastectomy offers
Factors that tend to favour mastectomy:
- Tumours are widely distributed across the breast and removing them would leave insufficient breast tissue for a functional or cosmetically acceptable result
- Clean surgical margins cannot be reliably achieved after reasonable attempts at removal
- A confirmed high-risk gene mutation exists and you prefer the risk reduction mastectomy provides
- Radiotherapy isn't an option - for example, following prior chest radiotherapy
- After being fully informed of all options, your personal preference is for mastectomy, for peace of mind or other reasons
If you have been told mastectomy is your only option and you are not clear on why, seeking a second opinion from a specialist oncoplastic surgeon is a reasonable next step. Our article on what to do when mastectomy has been recommended explains what questions to ask and where to find specialist input.
How does mastectomy compare with breast-conserving surgery for multifocal and multicentric breast cancer?
| Factor | Mastectomy | Breast-Conserving Surgery + Radiotherapy |
|---|---|---|
| Who is eligible | Almost all multifocal and multicentric cases | Selected cases where clean margins are achievable and breast volume allows good results |
| Breast preserved? | No - reconstruction can follow immediately or at a later date | Yes, though oncoplastic reshaping may alter size or shape |
| Radiotherapy needed after surgery | Not always required - depends on nodal status, margins, and other clinical factors | Yes - a standard, required part of breast-conserving treatment |
| Local recurrence risk | Generally low; comparable to BCS in contemporary series when radiotherapy is appropriately delivered | Comparable to mastectomy in selected patients when radiotherapy is given - see sources below |
| Robotic technique available | Yes - robotic nipple-sparing mastectomy via armpit incision at specialist centres | Robotic-assisted and oncoplastic minimally invasive approaches at specialist centres |
| Recovery | Longer initial recovery than BCS; immediate reconstruction extends this further | Shorter initial recovery than mastectomy; radiotherapy course adds several weeks of treatment |
Sources: "Multifocal and multicentric breast cancer, is it time to think again?" - Frontiers in Oncology; Oncoplastic BCS for synchronous multicentric and multifocal tumours - matched cohort analysis; Local control BCS vs mastectomy in multifocal/multicentric disease - systematic review and meta-analysis. Recovery descriptions are qualitative guides; individual experience will vary.
Both approaches can produce good outcomes when matched carefully to the right patient. The most important factor is that your surgical plan reflects your cancer's specific biology, your anatomy, your personal priorities, and input from a multidisciplinary team that includes an oncoplastic surgeon.
The role of neoadjuvant therapy in widening your options
If your tumours are currently too large or too numerous to safely remove through breast-conserving surgery, your oncologist may recommend chemotherapy or targeted drug therapy before surgery. This is called neoadjuvant therapy. For women whose tumours respond well, it may shrink the foci enough that breast-conserving surgery becomes possible where it was not before.
For multifocal and multicentric disease, neoadjuvant therapy can change your eligibility for breast conservation. This is worth asking your oncologist directly: "Would neoadjuvant treatment improve my chances of being eligible for breast-conserving surgery?" Ask this before surgery is scheduled.
What this means for UK women considering specialist surgery
In the UK, NHS breast cancer teams are experienced and follow evidence-based national guidelines. However, access to specialist oncoplastic and robotic breast surgery can vary between centres. For a diagnosis as specific as multifocal or multicentric disease - where a surgical plan truly benefits from specialist oncoplastic input - some women seek an additional opinion at a specialist centre or explore options at high-volume programmes abroad.
Some UK women have looked to specialist breast surgery centres in India, where oncoplastic and robotic techniques are used at high volume and at a fraction of UK private costs, with shorter wait times. If you are working through your current UK surgical plan and want an expert perspective before committing, you can explore alternatives to mastectomy with the Art of Healing Cancer team.
If you pursue surgery abroad and plan to continue radiotherapy or systemic treatment in the UK, our article on splitting your breast cancer care across two countries covers the practical steps involved in coordinating care across locations.
For a broader data-led comparison of recurrence risk between lumpectomy and mastectomy in early-stage disease, our article on recurrence risk after robotic lumpectomy vs mastectomy sets out the evidence clearly.
Questions to raise with your surgical team before deciding
- Are my tumours classified as multifocal or multicentric, and what does that mean for my surgical options?
- What is the combined size and distribution of the foci to be removed, and how much breast tissue would remain?
- Has my case been reviewed by an oncoplastic surgeon, not only a general breast surgeon?
- Would neoadjuvant chemotherapy or hormone therapy improve my eligibility for breast-conserving surgery?
- If breast-conserving surgery is attempted, what are the realistic chances of achieving clean margins across all tumour sites?
- What radiotherapy would I need after breast-conserving surgery, and over what period?
- If I choose mastectomy, what reconstruction options are available, and when can they be done?
If you want to review your options with a specialist team before committing to a plan, you can submit a discreet enquiry through BreastCancer.One. Female coordinators are available for all initial conversations.
When to talk to your doctor
Talk to your oncologist or breast surgeon as soon as possible if you have received a diagnosis of multifocal or multicentric breast cancer and have not yet had a full discussion of both breast-conserving and mastectomy options, including oncoplastic and robotic approaches. If your current team does not include an oncoplastic surgeon, ask for a referral or a second opinion at a specialist centre. You have the right to understand all your options before surgery.
This article is for general information and does not replace medical advice. Always consult your oncologist or care team about your specific situation.